MCID: NRC002
MIFTS: 51

Narcolepsy

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Narcolepsy

MalaCards integrated aliases for Narcolepsy:

Name: Narcolepsy 12 74 52 25 53 36 54 43 15 62 71
Narcolepsy-Cataplexy Syndrome 52 71
Narcoleptic Syndrome 52 25
Gelineau Syndrome 52 25
Paroxysmal Sleep 12 52
Narcolepsy, Without Cataplexy 12
Gelineau's Syndrome 52

Classifications:



External Ids:

Disease Ontology 12 DOID:8986
KEGG 36 H01293
ICD9CM 34 347.0
MeSH 43 D009290
NCIt 49 C84489
SNOMED-CT 67 60380001
ICD10 32 G47.41 G47.419
UMLS 71 C0027404 C0751362

Summaries for Narcolepsy

Genetics Home Reference : 25 Narcolepsy is a chronic sleep disorder that disrupts the normal sleep-wake cycle. Although this condition can appear at any age, it most often begins in adolescence. Narcolepsy is characterized by excessive daytime sleepiness. Affected individuals feel tired during the day, and several times a day they may experience an overwhelming urge to sleep. "Sleep attacks" can occur at unusual times, such as during a meal or in the middle of a conversation. They last from a few seconds to a few minutes and often lead to a longer nap, after which affected individuals wake up feeling refreshed. Another common feature of narcolepsy is cataplexy, which is a sudden loss of muscle tone in response to strong emotion (such as laughing, surprise, or anger). These episodes of muscle weakness can cause an affected person to slump over or fall, which occasionally leads to injury. Episodes of cataplexy usually last just a few seconds, and they may occur from several times a day to a few times a year. Most people diagnosed with narcolepsy also have cataplexy. However, some do not, which has led researchers to distinguish two major forms of the condition: narcolepsy with cataplexy and narcolepsy without cataplexy. Narcolepsy also affects nighttime sleep. Most affected individuals have trouble sleeping for more than a few hours at night. They often experience vivid hallucinations while falling asleep (hypnogogic hallucinations) or while waking up (hypnopompic hallucinations). Affected individuals often have realistic and distressing dreams, and they may act out their dreams by moving excessively or talking in their sleep. Many people with narcolepsy also experience sleep paralysis, which is an inability to move or speak for a short period while falling asleep or awakening. The combination of hallucinations, vivid dreams, and sleep paralysis is often frightening and unpleasant for affected individuals. Some people with narcolepsy have all of the major features of the disorder, while others have only one or two. Most of the signs and symptoms persist throughout life, although episodes of cataplexy may become less frequent with age and treatment.

MalaCards based summary : Narcolepsy, also known as narcolepsy-cataplexy syndrome, is related to narcolepsy 1 and cerebellar ataxia, deafness, and narcolepsy, autosomal dominant, and has symptoms including hemiplegia, excessive daytime somnolence and snoring. An important gene associated with Narcolepsy is PICSAR (P38 Inhibited Cutaneous Squamous Cell Carcinoma Associated LincRNA), and among its related pathways/superpathways are Hematopoietic cell lineage and Rheumatoid arthritis. The drugs Gabapentin and Lacosamide have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye.

Disease Ontology : 12 A sleep disorder that involves an excessive urge to sleep at inappropriate times, such as while at work.

NIH Rare Diseases : 52 Narcolepsy is a chronic brain disorder that involves poor control of sleep-wake cycles. People with narcolepsy have episodes of extreme daytime sleepiness and sudden, irresistible bouts of sleep (called "sleep attacks") that can occur at any time, and may last from seconds or minutes. Other signs and symptoms may include cataplexy (a sudden loss of muscle tone that makes a person go limp or unable to move); vivid dream-like images or hallucinations; and/or total paralysis just before falling asleep or after waking-up. Narcolepsy may have several causes, the most common being low levels of the neurotransmitter hypocretin (for various possible reasons). The disorder is usually sporadic but some cases are familial . There is no cure, but some symptoms can be managed with medicines and lifestyle changes.

NINDS : 53 Narcolepsy is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles. Many people with narcolepsy also experience uneven and interrupted sleep that can involve waking up frequently during the night.  At various times throughout the day, people with narcolepsy experience overpowering bouts of sleep. If the urge becomes overwhelming, individuals will fall asleep for periods lasting from a few seconds to several minutes. In rare cases, some people may remain asleep for an hour or longer.  In addition to excessive daytime sleepiness (EDS), people with narcolepsy experience some or all of the typical symptoms of cataplexy (the sudden loss of voluntary muscle tone), vivid hallucinations during sleep onset or upon awakening, and brief episodes of total paralysis at the beginning or end of sleep called sleep paralysis).  Because narcolepsy is often misdiagnosed as other conditions, it may take years to get the proper diagnosis. The cause of narcolepsy remains unknown.  It is likely that narcolepsy involves multiple factors interacting to cause neurological dysfunction and sleep disturbances.

KEGG : 36 Narcolepsy is a disabling sleep disorder characterized by irresistible excessive daytime sleepiness and cataplexy, a condition triggered by strong emotions leading to a sudden loss of muscle tone. Narcolepsy is a rare and mainly sporadic disorder. Familial narcolepsy accounts for less than 10% of all narcolepsy cases, and causative mutations have not been identified to date. The discovery of hypocretin-1 (HCRT) deficiency shed light on the underlying pathophysiology of the disease. The hypocretin neurotransmission system was shown to play a major role in controlling vigilance states. Because of the strong HLA association, hypocretin deficiency is believed to be caused by an autoimmune attack. It has also been reported that a missense mutation in myelin oligodendrocyte glycoprotein (MOG) is the cause of narcolepsy.

PubMed Health : 62 About narcolepsy: Narcolepsy (NAR-ko-lep-se) is a disorder that causes periods of extreme daytime sleepiness. The disorder also may cause muscle weakness. Most people who have narcolepsy have trouble sleeping at night. Some people who have the disorder fall asleep suddenly, even if they're in the middle of talking, eating, or another activity. Narcolepsy also can cause:

Wikipedia : 74 Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake... more...

Related Diseases for Narcolepsy

Diseases in the Narcolepsy family:

Narcolepsy 1 Narcolepsy 2
Narcolepsy 3 Narcolepsy 4
Narcolepsy 5 Narcolepsy 6
Narcolepsy 7

Diseases related to Narcolepsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 334)
# Related Disease Score Top Affiliating Genes
1 narcolepsy 1 35.4 P2RY11 MOG HLA-DQB1 HCRT
2 cerebellar ataxia, deafness, and narcolepsy, autosomal dominant 35.0 HCRT DNMT1
3 narcolepsy 2 35.0 NRCLP2 HLA-DQB1 HCRT
4 idiopathic hypersomnia 33.9 HLA-DQB1 HCRT
5 hypersomnia 33.7 HLA-DQB1 HCRT
6 sleep disorder 33.5 TNF MOG HCRTR2 HCRTR1 HCRT ATXN3
7 sleep apnea 32.1 TNF HCRTR2 HCRT
8 autoimmune disease 31.6 TNF MOG HLA-DQB1 HLA-DQA1 DNMT1
9 kleine-levin hibernation syndrome 31.3 HLA-DQB1 HCRT
10 guillain-barre syndrome 31.1 TNF MOG HLA-DQB1 HLA-DQA1 HCRT
11 periodic limb movement disorder 31.1 HCRTR2 HCRT
12 recurrent hypersomnia 30.9 HLA-DQB1 HCRTR2 HCRT
13 acute disseminated encephalomyelitis 30.9 MOG HLA-DQB1 HLA-DQA1 HCRT
14 neurosarcoidosis 30.8 TNF MOG
15 alopecia areata 30.7 TNF HLA-DQB1 HLA-DQA1
16 optic neuritis 30.6 TNF MOG HLA-DQA1
17 peripheral nervous system disease 30.5 TNF NPTX2 MOG ATXN3
18 optic nerve disease 30.3 TNF NPTX2 MOG
19 hashimoto thyroiditis 29.9 TNF HLA-DQB1 HLA-DQA1
20 narcolepsy 7 12.7
21 narcolepsy 5 12.4
22 narcolepsy 4 12.4
23 narcolepsy 6 12.4
24 narcolepsy 3 12.4
25 disseminated sclerosis with narcolepsy 12.3
26 achalasia, familial esophageal 10.7 HLA-DQB1 HLA-DQA1
27 primary adrenal insufficiency 10.7 HLA-DQB1 HLA-DQA1
28 beryllium disease 10.7 TNF HLA-DQB1 HLA-DQA1
29 rohhad 10.7 HCRTR2 HCRTR1 HCRT
30 oligoarticular juvenile idiopathic arthritis 10.7 TNF HLA-DQB1 HLA-DQA1
31 endometritis 10.7 TNF HLA-DQB1 HLA-DQA1
32 chronic beryllium disease 10.7 TNF HLA-DQB1
33 von economo's disease 10.7 HCRTR2 HCRTR1 HCRT
34 dermatitis herpetiformis 10.7 TNF HLA-DQB1 HLA-DQA1
35 rheumatic fever 10.7 TNF HLA-DQB1 HLA-DQA1
36 primary progressive multiple sclerosis 10.7 TNF MOG HLA-DQB1
37 rubella 10.7 TNF MOG HLA-DQB1 HLA-DQA1
38 autoimmune disease of gastrointestinal tract 10.6 TNF HLA-DQB1 HLA-DQA1
39 autoimmune hepatitis type 1 10.6 HLA-DQB1 HLA-DQA1
40 pediatric multiple sclerosis 10.6 MOG HLA-DQB1
41 focal epithelial hyperplasia 10.6 HLA-DQB1 HLA-DQA1
42 calcinosis 10.6 TNF HLA-DQB1 HLA-DQA1
43 toxoplasmosis 10.6 TNF HLA-DQB1 HLA-DQA1
44 juvenile rheumatoid arthritis 10.6 TNF HLA-DQB1 HLA-DQA1
45 podoconiosis 10.6 HLA-DQB1 HLA-DQA1
46 idiopathic bronchiectasis 10.5 HLA-DQB1 HLA-DQA1
47 rem sleep behavior disorder 10.5
48 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.5
49 influenza 10.4
50 autoimmune disease of peripheral nervous system 10.4 TNF MOG

Comorbidity relations with Narcolepsy via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism

Graphical network of the top 20 diseases related to Narcolepsy:



Diseases related to Narcolepsy

Symptoms & Phenotypes for Narcolepsy

UMLS symptoms related to Narcolepsy:


hemiplegia, excessive daytime somnolence, snoring, sleep disturbances, sleeplessness, sluggishness

Drugs & Therapeutics for Narcolepsy

PubMed Health treatment related to Narcolepsy: 62

Narcolepsy has no cure. However, medicines, lifestyle changes, and other therapies can relieve many of its symptoms. Treatment for narcolepsy is based on the type of symptoms you have and how severe they are. Not all medicines and lifestyle changes work for everyone. It may take weeks to months for you and your doctor to find the best treatment .

Drugs for Narcolepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
2
Lacosamide Approved Phase 4 860352-01-8, 175481-36-4 219078
3
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Ribavirin Approved Phase 4 36791-04-5 37542
6
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
7
Rasagiline Approved Phase 4 136236-51-6 3052776
8 Pharmaceutical Solutions Phase 4
9 Psychotropic Drugs Phase 4
10 Sodium Channel Blockers Phase 4
11 Diuretics, Potassium Sparing Phase 4
12 Analgesics Phase 4
13 Anti-Anxiety Agents Phase 4
14 Tranquilizing Agents Phase 4
15 Anticonvulsants Phase 4
16 Antimanic Agents Phase 4
17 Excitatory Amino Acid Antagonists Phase 4
18 Excitatory Amino Acids Phase 4
19 Sympathomimetics Phase 4
20 Autonomic Agents Phase 4
21 Neurotransmitter Agents Phase 4
22 Protective Agents Phase 4
23 Cytochrome P-450 CYP3A Inducers Phase 4
24 Central Nervous System Stimulants Phase 4
25 Dopamine Agents Phase 4
26 Antiparkinson Agents Phase 4
27 Antioxidants Phase 4
28 Interferon-alpha Phase 4
29 interferons Phase 4
30 Neuroprotective Agents Phase 4
31 Dopamine agonists Phase 4
32 Monoamine Oxidase Inhibitors Phase 4
33
Morphine Approved, Investigational Phase 3 57-27-2 5288826
34
Histamine Approved, Investigational Phase 3 51-45-6 774
35
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
36
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
37
Histamine Phosphate Phase 3 51-74-1 65513
38 Histamine H3 Antagonists Phase 3
39 Vitamins Phase 3
40 Trace Elements Phase 3
41 Micronutrients Phase 3
42 Vitamin B 6 Phase 3
43 Vitamin B Complex Phase 3
44 Nutrients Phase 3
45 Vitamin B9 Phase 3
46 Folate Phase 3
47 Narcotics Phase 3
48 Analgesics, Opioid Phase 3
49
Pyridoxal Experimental, Nutraceutical Phase 3 66-72-8 1050
50
Flumazenil Approved Phase 1, Phase 2 78755-81-4 3373

Interventional clinical trials:

(show top 50) (show all 138)
# Name Status NCT ID Phase Drugs
1 Single Center, Therapeutic Exploratory Clinical Trial to Evaluate the Safety of Sodium Oxybate (Xyrem) 500 mg/mL Oral Solution on Potential Endocrine Changes at Currently Labeled Therapeutic Dose Regimens (4.5 - 9 g/Day Divided Into Two Equal Doses) During 12 Weeks of Treatment of Cataplexy in Adult Patients With Narcolepsy. Completed NCT00345800 Phase 4 Sodium Oxybate (Xyrem)
2 Modafinil Treatment for Fatigue in HIV+ Patients Completed NCT00118378 Phase 4 Modafinil;Placebo
3 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4 armodafinil;placebo
4 Slow-wave Sleep and Daytime Functioning in Chronic Fatigue Syndrome: Effects of Sodium Oxybate Completed NCT02055898 Phase 4 Sodium Oxybate
5 The Effect of Armodafinil (Nuvigil) on Fatigue and Quality of Life in Peri- and Postmenopausal Women Completed NCT01460628 Phase 4 Armodafinil
6 An Open Label, Single-Center Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies Completed NCT01023672 Phase 4 Armodafinil
7 A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip Completed NCT02155257 Phase 4 Modafinil;Gabapentin;Placebo
8 Searching for "Sleep Friendly" Therapies for a Sleepy Population: A Double-Blind, Placebo-Controlled, Randomized Trial to Assess the Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy Completed NCT01190098 Phase 4 Lacosamide;Placebo
9 Does Xyrem Influence Brain Dopamine in Patients With Narcolepsy? A PET Imaging Investigation Recruiting NCT02637076 Phase 4 Xyrem
10 A Pilot, Multiple Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Use of Methylphenidate for Cognitive and Behavioral Symptoms in Mild Cognitive Impairment and Dementia Recruiting NCT03811847 Phase 4 Methylphenidate Extended Release Oral Capsule
11 Sodium Oxybate in Treatment-Resistant REM Sleep Behavior Disorder (RBD): A Randomized Placebo-Controlled Trial Recruiting NCT04006925 Phase 4 Sodium Oxybate
12 Modafinil Treatment for Sleep/Wake Disturbances in Older Adults Terminated NCT00626210 Phase 4 modafinil
13 Armodafinil for Patients Starting Hepatitis C Treatment Terminated NCT01470651 Phase 4 Armodafinil;Sugar Pill
14 Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease Terminated NCT01048229 Phase 4 Rasagiline;Pramipexole
15 Prospective Randomized Study Evaluating the Effects of Modafinil in Patients Receiving Oral Morphine for Pain Palliation Unknown status NCT01766323 Phase 3 Modafinil;Placebo
16 A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy Completed NCT02221869 Phase 3 Xyrem
17 A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 and 250 mg/Day) as Treatment for Adults With Excessive Sleepiness Associated With Narcolepsy Completed NCT00078377 Phase 3 Armodafinil;Armodafinil;Placebo
18 A 6-Month Open Label, Flexible-Dosage Study to Assess the Safety and Effectiveness of PROVIGIL (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00214968 Phase 3 Modafinil
19 A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy Completed NCT02348593 Phase 3 JZP-110;Placebo oral tablet
20 Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) and Modafinil With Placebo in Treatment of Daytime Sleepiness in Narcolepsy Completed NCT00066170 Phase 3 Xyrem;Xyrem Placebo;Modafinil at established dose;Modafinil (Placebo)
21 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) With Placebo for the Treatment of Narcolepsy Completed NCT00049803 Phase 3 sodium oxybate
22 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of PROVIGIL ® (Modafinil) Treatment (100, 200, and 400 mg/Day) in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Completed NCT00107796 Phase 3 Modafinil
23 A Long-Term Safety and Maintenance of Efficacy Study ofJZP-110 [(R)-2-amino-3 Phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or Obstructive Sleep Apnea Completed NCT02348632 Phase 3 JZP-110
24 A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period) Completed NCT00228553 Phase 3 Armodafinil 100 to 250 mg/day
25 A 1 Year Open Label, Flexible Dosage Extension Study to Assess the Safety and Continued Effectiveness of PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00107848 Phase 3 Modafinil
26 Prospective, Randomized, Double-blind Study, Placebo-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01067222 Phase 3 BF2.649;Modafinil;Placebo
27 A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Study of the Safety and Efficacy of CEP-10953 in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period) Completed NCT00078312 Phase 3 CEP-10953 (Armodafinil)
28 An Open-label Naturalistic Pragmatic Study to Assess the Long Term Safety of BF2.649 (Pitolisant) in the Treatment of Excessive Daytime Sleepiness (EDS) in Narcolepsy (12 Months Follow-up, Followed by a Prolonged Follow up) Completed NCT01399606 Phase 3 BF2.649
29 A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy. Completed NCT01800045 Phase 3 Pitolisant;Placebo
30 A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy Completed NCT03030599 Phase 3 JZP-258
31 Long-Term, Open-Label, Multi-Center Extension Trial of Xyrem® (Sodium Oxybate) Oral Solution for the Treatment of Narcolepsy Completed NCT00132873 Phase 3 Xyrem (sodium oxybate) oral solution
32 Prospective, Randomized, Double-blind Study, Parallel-group, Multi-center Trial Assessing the Effects of Escalating Doses of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolepsy Completed NCT01067235 Phase 3 BF2.649;BF2.649 add on Modafinil
33 Randomized, Double-blind, Placebo and Comparator-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy Completed NCT01638403 Phase 3 BF2.649;Vigil;palcebo
34 A Short-term (8 Week) Open-Label Study, Followed by a Long Term Evaluation, to Assess Patient-Reported Outcomes With Armodafinil Treatment (150 to 250 mg/Day) for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00228566 Phase 3 Armodafinil
35 Double Blind Randomized Study to Assess the Efficacy of BF2.649 Compared to Placebo in add-on to Sodium Oxybate in the Treatment of Narcoleptic Patients With Residual Excessive Daytime Sleepiness (EDS) During 8 Weeks Completed NCT01789398 Phase 3 BF2.649
36 Methylphenidate to Improve Balance and Walking in MS Completed NCT01896700 Phase 2, Phase 3 Methylphenidate;Placebo
37 Randomized Controlled Study to Evaluate the Effects of Modafinil in Cancer Related Fatigue in Patients Undergoing Radiation Therapy Completed NCT01440621 Phase 3 Modafinil;Pyridoxine
38 The Effects of Armodafinil (Nuvigil) on Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients Completed NCT02478580 Phase 3 Nuvigil;Placebo
39 A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects With Narcolepsy Active, not recruiting NCT02720744 Phase 3 Sodium Oxybate;Placebo
40 A Randomized Double-Blinded, Placebo Controlled, Crossover Trial Examining the Effectiveness of Modafinil in Opioid Induced Sedation Terminated NCT00267332 Phase 3 Modafinil
41 Modafinil in the Treatment of Fatigue in Post-Polio Syndrome Terminated NCT00067496 Phase 3 Modafinil
42 Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence Unknown status NCT00123383 Phase 2 Modafinil
43 Randomised Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence Unknown status NCT00123370 Phase 2 Modafinil
44 A Phase II, Prospective, Randomized, Double-blind, Crossover Placebo-controlled Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease Unknown status NCT02111122 Phase 2 Sodium Oxybate
45 Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Methylphenidate Hydrochloride as a Treatment for Chronic Fatigue Syndrome in Patients Taking a CFS-Specific Nutrient Formula Unknown status NCT01966276 Phase 2 Methyl-P plus Nutrient Formula;Methyl-P plus Nutrient matched placebos
46 Phase IIa Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of KPAX 002 (Methylphenidate Hydrochloride + K-PAX Synergy) as a Treatment for Gulf War Illness in Patients Meeting the Kansas Case Definition Unknown status NCT02357030 Phase 2 Methyl-P plus GWI Nutrient Formula
47 A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Completed NCT02512588 Phase 2 BTD-001;Placebo
48 A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors Completed NCT01183312 Phase 1, Phase 2 Flumazenil
49 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2 Clarithromycin followed by placebo;Placebo then Clarithromycin
50 A Phase II, Double-blind, Parallel-group Comparative Study 2 of TS-091 in Patients With Narcolepsy Completed NCT03267303 Phase 2 TS-091 5mg;TS-091 10mg;Placebo

Search NIH Clinical Center for Narcolepsy

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Amphetamine
AMPHETAMINE ADIPATE
Amphetamine aspartate
Amphetamine Sulfate
AMPHETAMINE/DEXTROAMPHETAMINE RESIN COMPLEX
Dextroamphetamine
DEXTROAMPHETAMINE ADIPATE
Dextroamphetamine saccharate
Dextroamphetamine Sulfate
Methamphetamine
Methylphenidate
Methylphenidate Hydrochloride
modafinil
Pemoline

Cochrane evidence based reviews: narcolepsy

Genetic Tests for Narcolepsy

Anatomical Context for Narcolepsy

MalaCards organs/tissues related to Narcolepsy:

40
Brain, Testes, Eye, T Cells, Hypothalamus, Heart, Amygdala

Publications for Narcolepsy

Articles related to Narcolepsy:

(show top 50) (show all 4377)
# Title Authors PMID Year
1
Narcolepsy in Parkinson's disease. 54 61
20518604 2010
2
Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss? 54 61
20403960 2010
3
Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights. 54 61
20425033 2010
4
Hypocretin/orexin and narcolepsy: new basic and clinical insights. 54 61
19555382 2010
5
Emerging treatments for narcolepsy and its related disorders. 54 61
20166851 2010
6
Reduced amygdala activity during aversive conditioning in human narcolepsy. 54 61
20373351 2010
7
Monoaminergic neuronal changes in orexin deficient mice. 54 61
19703479 2010
8
Rapid eye movement sleep behaviour disorder in patients with narcolepsy is associated with hypocretin-1 deficiency. 54 61
20129934 2010
9
Anxiety and mood disorders in narcolepsy: a case-control study. 54 61
20114128 2010
10
Body mass index-independent metabolic alterations in narcolepsy with cataplexy. 54 61
19928388 2009
11
[Hypocretin system and narcolepsy]. 54 61
20011964 2009
12
Distribution of neurochemical abnormalities in patients with narcolepsy with cataplexy: An in vivo brain proton MR spectroscopy study. 54 61
19463917 2009
13
Cell transplantation: a future therapy for narcolepsy? 54 61
19689312 2009
14
Absence of ubiquitinated inclusions in hypocretin neurons of patients with narcolepsy. 54 61
19687452 2009
15
Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. 54 61
19725250 2009
16
CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. 54 61
19238805 2009
17
IGFBP3 colocalizes with and regulates hypocretin (orexin). 54 61
19158946 2009
18
The signalling profile of recombinant human orexin-2 receptor. 54 61
18599270 2008
19
[Narcolepsy with cataplexy]. 54 61
18805301 2008
20
Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. 54 61
18714784 2008
21
Normal levels of cerebrospinal fluid hypocretin-1 and daytime sleepiness during attacks of relapsing-remitting multiple sclerosis and monosymptomatic optic neuritis. 54 61
18505777 2008
22
Narcolepsy: immunological aspects. 54 61
18291691 2008
23
The hypocretin neurotransmission system in myotonic dystrophy type 1. 54 61
18195268 2008
24
Prevalence of HLA DQB1*0602 allele in patients with migraine. 54 61
18345414 2007
25
The hypocretin/orexin receptor: therapeutic prospective in sleep disorders. 54 61
17970638 2007
26
Review of pathophysiology and clinical management of narcolepsy in dogs. 54 61
17873267 2007
27
[Hypocretins, peptides associated with narcolepsy]. 54 61
18246936 2007
28
The hypothalamic peptidergic system, hypocretin/orexin and vigilance control. 54 61
17376528 2007
29
Isolated mediotegmental lesion causing narcolepsy and rapid eye movement sleep behaviour disorder: a case evidencing a common pathway in narcolepsy and rapid eye movement sleep behaviour disorder. 54 61
17369596 2007
30
Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patients. 54 61
17256150 2007
31
Neuropeptides as possible targets in sleep disorders: special emphasis on hypocretin-deficient narcolepsy. 54 61
17305553 2007
32
Narcolepsy: pathophysiology and pharmacology. 54 61
18078360 2007
33
[Hypocretins: involvement in the regulation of sleep-wakefulness cycle and pathogenesis of narcolepsy]. 54 61
17245312 2007
34
Hypocretin/Orexin: a molecular link between sleep, energy regulation, and pleasure. 54 61
18070844 2007
35
Reduced hypothalamic gray matter in narcolepsy with cataplexy. 54 61
17187022 2006
36
Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings. 54 61
17162990 2006
37
Narcolepsy and the hypocretins. 54 61
16979425 2006
38
Narcolepsy and the hypocretin system--where motion meets emotion. 54 61
16990828 2006
39
Sex difference in body weight gain and leptin signaling in hypocretin/orexin deficient mouse models. 54 61
16626839 2006
40
CSF versus serum leptin in narcolepsy: is there an effect of hypocretin deficiency? 54 61
16944669 2006
41
The neurobiology of hypocretins (orexins), narcolepsy and related therapeutic interventions. 54 61
16766052 2006
42
Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. 54 61
16774153 2006
43
Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy. 54 61
16484654 2006
44
Molecular genetics and treatment of narcolepsy. 54 61
16754256 2006
45
Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. 54 61
16247044 2005
46
Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. 54 61
16135770 2005
47
Clock gene polymorphisms and narcolepsy in positive and negative HLA-DQB1*0602 patients. 54 61
16125818 2005
48
Hypocretins (orexins) and sleep-wake disorders. 54 61
16168936 2005
49
Hypocretins (orexins): clinical impact of the discovery of a neurotransmitter. 54 61
15979356 2005
50
Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. 54 61
16006155 2005

Variations for Narcolepsy

Copy number variations for Narcolepsy from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 177309 3 55147029 55255377 Insertion HCRTR2 Narcolepsy

Expression for Narcolepsy

Search GEO for disease gene expression data for Narcolepsy.

Pathways for Narcolepsy

Pathways related to Narcolepsy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.13 TNF HLA-DQB1 HLA-DQA1
2 10.77 TNF HLA-DQB1 HLA-DQA1

GO Terms for Narcolepsy

Cellular components related to Narcolepsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II protein complex GO:0042613 8.62 HLA-DQB1 HLA-DQA1

Biological processes related to Narcolepsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.5 HCRTR2 HCRTR1 HCRT
2 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.33 P2RY11 HCRTR2 HCRT
3 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.26 HLA-DQB1 HLA-DQA1
4 feeding behavior GO:0007631 9.13 HCRTR2 HCRTR1 HCRT
5 chemical synaptic transmission GO:0007268 9.02 NPTX2 HCRTR2 HCRTR1 HCRT ATXN3

Molecular functions related to Narcolepsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 8.96 HLA-DQB1 HLA-DQA1
2 orexin receptor activity GO:0016499 8.62 HCRTR2 HCRTR1

Sources for Narcolepsy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....